High-Purity Cefazolin Sodium | CAS 27164-46-1 API

Understanding Cefazolin Sodium: A Cornerstone in Antimicrobial Therapy

In the dynamic landscape of pharmaceutical raw materials, cefazolin sodium stands out as a critical first-generation cephalosporin antibiotic, widely recognized for its broad-spectrum bactericidal activity against a variety of Gram-positive and some Gram-negative bacteria. Its efficacy, combined with a favorable safety profile, makes it an indispensable active pharmaceutical ingredient (API) in the treatment and prevention of numerous bacterial infections, including surgical prophylaxis, respiratory tract infections, skin and soft tissue infections, and urinary tract infections. As a semi-synthetic derivative of cephalosporin C, this compound, identified by its Chemical Abstracts Service (CAS) No. 27164-46-1, is primarily administered parenterally, offering rapid onset of action and reliable systemic distribution. The demand for high-purity, stable cefazolin sodium has seen consistent growth, driven by increasing global healthcare needs and the persistent threat of bacterial resistance, necessitating a focus on superior quality and consistent supply from reputable manufacturers. Industry trends indicate a sustained investment in advanced synthesis techniques and stringent quality control measures to meet the evolving regulatory landscapes and ensure therapeutic effectiveness. The strategic importance of this API extends beyond its immediate therapeutic applications; it underscores the critical need for robust supply chains capable of delivering consistent quality on a global scale, supporting pharmaceutical companies in their mission to provide life-saving medications. Manufacturers must not only adhere to current Good Manufacturing Practices (cGMP) but also demonstrate profound expertise in chemical synthesis, purification, and analytical validation to maintain leadership in this highly competitive and regulated market segment.

Precision Manufacturing: The Cefazolin Sodium Synthesis Journey

The manufacturing process of cefazolin sodium is a sophisticated multi-step chemical synthesis, requiring precise control at every stage to ensure the desired purity, potency, and physical characteristics of the final API. It typically commences with the enzymatic or chemical conversion of penicillin G or 7-aminocephalosporanic acid (7-ACA) to an intermediate, followed by several carefully orchestrated chemical reactions involving specific acylating agents and solvents. Key steps often include esterification, amidation, and salt formation, each optimized to maximize yield and minimize impurities. For instance, the introduction of a methylthiadiazole group is characteristic of cefazolin sodium's structure, contributing to its unique pharmacokinetic and pharmacodynamic properties. Post-synthesis, rigorous purification techniques such as crystallization, filtration, and drying are employed. Crystallization is particularly crucial as it directly impacts the product's crystallinity, particle size distribution, and bulk density, which are vital for subsequent formulation steps by pharmaceutical clients. Drying is performed under controlled conditions to achieve specific moisture content, ensuring stability and preventing degradation. Throughout the entire process, adherence to cGMP guidelines is paramount, covering everything from raw material sourcing and in-process controls to final product release testing. This meticulous attention to detail ensures that each batch of cefazolin sodium consistently meets stringent pharmacopoeial standards such as USP (United States Pharmacopeia), EP (European Pharmacopoeia), BP (British Pharmacopoeia), and JP (Japanese Pharmacopoeia), as well as ICH (International Council for Harmonisation) guidelines for impurity profiles, stability, and dissolution. This robust manufacturing framework not only guarantees product quality but also underpins the reliability and safety expected from a leading API supplier.

Key Technical Parameters and Quality Assurance

The quality of cefazolin sodium is defined by a comprehensive set of technical parameters, each rigorously tested to ensure therapeutic efficacy and patient safety. These specifications are critical for pharmaceutical formulators, as they directly influence the API's behavior in dosage forms and its long-term stability. A typical specification sheet for high-grade cefazolin sodium would include an assay value, indicating the percentage of the active compound, typically exceeding 95.0% on an anhydrous basis to ensure potency. pH levels are carefully controlled, usually within a narrow range (e.g., 4.5-6.0 for a 10% solution), as deviations can affect solubility and stability, especially for injectable formulations. Water content, determined via Karl Fischer titration, is crucial to prevent hydrolysis and maintain stability during storage; it is typically kept below a specified limit (e.g., 6.0%). Specific optical rotation confirms the correct stereochemistry, a fundamental aspect of chiral drug substances, ensuring the biological activity is consistent. Perhaps most importantly, the profile of related substances or impurities is meticulously monitored using advanced chromatographic techniques like High-Performance Liquid Chromatography (HPLC). Limits for individual and total impurities are set extremely low to minimize potential adverse effects and ensure product purity. Heavy metals and bacterial endotoxins (LAL test) are also stringently controlled to ensure the product is safe for parenteral administration, with limits often at parts per million (ppm) or endotoxin units (EU) per milligram. These parameters collectively form the cornerstone of quality assurance, validating the API's suitability for pharmaceutical use and reinforcing manufacturer credibility through transparent, data-driven quality control.

Typical Specifications for Cefazolin Sodium (CAS No.: 27164-46-1)

Applications, Industry Trends, and Strategic Advantages

Cefazolin sodium's robust antimicrobial profile makes it a versatile API with widespread applications across various medical domains. Its primary utility lies in the prophylaxis and treatment of bacterial infections, particularly those caused by susceptible strains of Staphylococcus aureus (including methicillin-sensitive strains), Streptococcus pneumoniae, and various Gram-negative rods. In surgical settings, it is a first-line agent for preventing postoperative infections across a spectrum of procedures, from general surgery to orthopedic and cardiothoracic interventions, owing to its predictable pharmacokinetics and good tissue penetration. Beyond surgery, it is a go-to choice for skin and soft tissue infections, bone and joint infections, and certain respiratory tract infections. Current industry trends reflect an emphasis on optimizing supply chain resilience and ensuring consistent availability of critical APIs like cefazolin sodium, particularly in light of global disruptions. Pharmaceutical manufacturers are increasingly seeking API suppliers who not only meet stringent quality and regulatory standards but also offer competitive pricing, robust technical support, and the flexibility for customized solutions. Furthermore, there's a growing focus on sustainable manufacturing practices and reducing the environmental footprint of chemical synthesis. Suppliers who can demonstrate commitments to green chemistry principles and energy efficiency gain a significant competitive edge. The ability to provide comprehensive regulatory documentation, such as Drug Master Files (DMFs) and Certificates of Suitability (CEPs), is also paramount, streamlining the drug approval process for clients worldwide. This strategic advantage extends to offering customized particle sizes, polymorphs, or specific impurity profiles tailored to a client's unique formulation needs, ensuring optimal performance in their final drug products.

Selecting Your API Partner: Beyond Product Specifications

Choosing the right API supplier for cefazolin sodium extends far beyond simply reviewing product specifications; it involves assessing the partner's intrinsic capabilities to ensure long-term reliability, regulatory compliance, and value addition. A truly superior supplier distinguishes itself through unwavering commitment to quality, backed by a comprehensive Quality Management System (QMS) that is regularly audited and updated to reflect the latest global cGMP standards. This includes not only robust in-process controls and final product testing but also meticulous vendor qualification for raw materials, ensuring traceability from source to finished product. Furthermore, a reputable supplier will possess extensive experience in navigating complex international regulatory landscapes, providing not just the API, but also comprehensive regulatory support, including readily available DMFs and CEPs for relevant markets. This proactive approach significantly de-risks the client's drug development and approval processes. Technical expertise is another cornerstone; a leading supplier offers dedicated scientific and technical teams capable of providing in-depth product knowledge, troubleshooting formulation challenges, and offering insights into the latest pharmacopoeial revisions for cefazolin sodium. This collaborative approach can significantly accelerate a client's time-to-market. Transparency in lead times, reliable logistics, and flexible delivery schedules are also vital, particularly for high-volume APIs, to ensure uninterrupted supply chains. Ultimately, the partnership with an API supplier is a long-term strategic alliance, where mutual trust, open communication, and a shared commitment to patient safety form the foundation for success. The ability to consistently deliver high-quality cefazolin sodium, alongside unparalleled service, is the hallmark of a truly valuable partner in the pharmaceutical industry.

Customized Solutions and Application Success Stories

In the highly competitive pharmaceutical market, the ability to offer customized solutions for cefazolin sodium API can be a decisive factor for pharmaceutical companies. Beyond standard pharmacopoeial grades, clients often require specific modifications to suit their unique formulation processes or target drug delivery systems. This might involve tailoring the particle size distribution (e.g., micronized grades for suspensions or specific bulk densities for capsule filling), controlling polymorphs to optimize stability or bioavailability, or adjusting the residual solvent profile to meet regional regulatory requirements. A truly customer-centric API manufacturer excels in these bespoke services, leveraging advanced R&D capabilities and a deep understanding of pharmaceutical engineering. For example, a client developing a novel injectable formulation might require cefazolin sodium with enhanced solubility kinetics and extremely low particulate matter, necessitating a specialized crystallization process and stringent filtration. A case study could highlight a partnership with a global generics manufacturer who faced challenges with batch-to-batch consistency for their existing cefazolin sodium supply. By collaborating closely, our technical team identified critical process parameters that influenced crystal morphology, leading to the development of a tailored manufacturing process that ensured uniform physical characteristics and improved dissolution profiles, resulting in reduced batch rejection rates and enhanced product stability for the client. Another example involves supporting a veterinary pharmaceutical company in developing a unique suspension formulation. Our expertise in controlling the suspension properties of cefazolin sodium API, coupled with providing comprehensive stability data under various climatic zones, enabled their successful product launch within a challenging timeline. These tailored approaches not only solve immediate formulation challenges but also foster long-term strategic partnerships built on trust and mutual success.

Frequently Asked Questions (FAQ) about Cefazolin Sodium API

1. What pharmacopoeial standards does your Cefazolin Sodium meet?

Our cefazolin sodium (CAS No.: 27164-46-1) consistently meets and often exceeds the stringent requirements of major global pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), British Pharmacopoeia (BP), and Japanese Pharmacopoeia (JP). We conduct comprehensive testing on every batch to ensure compliance with the latest monographs, covering aspects such as assay, impurity profile, pH, water content, specific optical rotation, and bacterial endotoxins. This multi-pharmacopoeial compliance simplifies the regulatory submission process for our clients operating in diverse international markets, providing a single high-quality source for their API needs. Our commitment to these standards is underpinned by a robust Quality Management System and a team of experienced analytical chemists.

2. Do you provide regulatory support and documentation, such as DMFs?

Absolutely. We understand the critical importance of robust regulatory documentation for our clients' drug registration processes. We maintain a comprehensive Drug Master File (DMF) for our cefazolin sodium with key regulatory agencies, including the FDA in the United States. Additionally, we provide Certificates of Suitability (CEPs or CoS) for the European market and other necessary technical documents to support your regulatory submissions worldwide. Our dedicated regulatory affairs team is available to assist with any specific documentation requests, Letter of Authorization (LOA) generation, or questions related to our API's regulatory status, ensuring a smooth and efficient approval pathway for your finished drug product. Our extensive experience in global regulatory filings helps clients navigate complex requirements with confidence.

3. What are your typical lead times and delivery capabilities for Cefazolin Sodium?

Our typical lead times for cefazolin sodium vary depending on order volume, existing stock levels, and specific customization requirements. However, we strive to maintain efficient production schedules and strategic inventory management to ensure prompt delivery. For standard orders, lead times typically range from 2 to 4 weeks after order confirmation. We work closely with our clients to understand their demand forecasts and establish reliable supply agreements, including just-in-time delivery options for high-volume users. Our robust logistics network, combined with secure packaging solutions compliant with pharmaceutical standards, ensures that the product arrives at your facility in optimal condition, maintaining its stability and integrity throughout transit. We are committed to transparency regarding delivery schedules and proactive communication in case of any unforeseen circumstances, ensuring supply chain reliability.

4. Can you provide custom specifications or particle sizes for Cefazolin Sodium?

Yes, leveraging our advanced R&D and manufacturing capabilities, we are well-equipped to provide cefazolin sodium with customized specifications tailored to your specific formulation needs. This includes adjusting particle size distribution (e.g., micronization for enhanced dissolution or suspension properties), controlling bulk density, or fine-tuning impurity profiles. We understand that optimal API characteristics are crucial for maximizing the performance and stability of your final drug product. Our technical team works collaboratively with clients to define precise requirements and validate the customized product through comprehensive analytical testing and stability studies. This bespoke approach underscores our commitment to being a flexible and responsive partner, helping our clients overcome unique formulation challenges and achieve their product development goals efficiently.

Why Partner with Us for Your Cefazolin Sodium Needs?

Choosing the right API partner is a strategic decision that impacts the quality, reliability, and success of your pharmaceutical products. For cefazolin sodium, our commitment transcends mere supply; we offer a partnership built on expertise, trust, and mutual growth. Our distinguished reputation is rooted in decades of specialized experience in synthesizing high-quality APIs, backed by state-of-the-art manufacturing facilities that adhere to the most rigorous international cGMP standards. We pride ourselves on an impeccable track record of regulatory compliance, as evidenced by successful audits from global health authorities and readily available DMFs and CEPs for our cefazolin sodium (CAS No.: 27164-46-1). Our technical advantage lies not only in our superior product quality, characterized by high purity, consistent particle size, and excellent stability, but also in our proactive approach to research and development, continuously seeking to enhance our synthesis processes and product profiles. We offer comprehensive customer support, from initial inquiry and technical consultation to post-delivery assistance, ensuring a seamless experience. Our robust supply chain management guarantees timely and secure global delivery, mitigating risks of stockouts and ensuring uninterrupted production for our clients. Furthermore, we provide flexible procurement options, competitive pricing models, and a commitment to long-term partnerships, adapting to the evolving needs of the pharmaceutical market. When you choose us, you're not just acquiring cefazolin sodium; you're investing in a reliable, expert-driven partnership dedicated to accelerating your product's journey to market and contributing to global health.

Conclusion and Outlook

The persistent global need for effective antimicrobial agents underscores the enduring importance of high-quality cefazolin sodium in modern medicine. As a first-generation cephalosporin, its established efficacy, favorable safety profile, and broad applicability continue to make it a cornerstone in the treatment and prevention of bacterial infections worldwide. The future trajectory for APIs like cefazolin sodium is shaped by several key factors: an escalating demand driven by an aging global population and rising healthcare expenditures, coupled with increasing stringency in regulatory oversight and a heightened focus on supply chain resilience. Manufacturers of this vital API must continually innovate in process efficiency, purity standards, and environmental sustainability to remain competitive and responsible. Furthermore, the ability to adapt to specific client needs—whether through customized physical properties, enhanced stability profiles, or expedited regulatory support—will increasingly define industry leaders. The market trend indicates a move towards strategic partnerships rather than transactional relationships, where API suppliers are seen as extensions of their clients' R&D and manufacturing teams. Our commitment to delivering superior quality cefazolin sodium (CAS No.: 27164-46-1), coupled with unparalleled technical expertise and customer support, positions us as an ideal partner for pharmaceutical companies globally. We are dedicated to contributing to public health by ensuring a reliable supply of essential medicines, driving innovation, and upholding the highest standards of pharmaceutical excellence.

References

1. United States Pharmacopeia. Cefazolin Sodium Monograph. USP 43–NF 38. United States Pharmacopeial Convention, Rockville, MD.
2. European Pharmacopoeia. Cefazolin Sodium Monograph. 10th Ed. Council of Europe, Strasbourg.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
4. Therapeutic Guidelines: Antibiotic. Cefazolin. Version 16. Melbourne: Therapeutic Guidelines Limited.